Hero

News & Events

Mestag in the News
BioCentury Article: Mestag: Attacking Tumors from Within

Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases

October 8, 2024

Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300

August 28, 2024

Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting

Mestag Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

February 28, 2024

View All Press Releases

PEGS Europe Protein & Antibody Engineering Summit – Barcelona, Spain

November 5-7, 2024

Conference Website

SITC 2024 Annual Meeting – Houston, Texas

November 8-10, 2024

Conference Website

BSI Immune Therapies Summit – Cambridge, UK

November 25-26, 2024

Conference Website